SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2011

SEGMENT INFORMATION [Abstract]

SEGMENT INFORMATION

NOTE 4. SEGMENT INFORMATION

We operate in one business segment: the research, development and commercialization of pharmaceutical products.  Our corporate headquarters in the United States collects product sales, licensing fees, royalties, and sponsored research revenues from our arrangements with external customers and licensees.  Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

Our revenues are currently derived primarily from one licensee for domestic activities, three licensees for international activities, and our sales force for the domestic sale of Altrazeal®.

Revenues per geographic area for the three and nine months ended September 30 are summarized as follows:

	Three Months Ended September 30,										Nine Months Ended September 30,
Revenues	2011		%			2010		%			2011		%			2010		%
Domestic	$	67,468		92	%	$	57,247		93	%	$	210,660		92	%	$	303,247		57	%
International		6,184		8	%		4,370		6	%		18,349		8	%		225,234		43	%
Total	$	73,652		100	%	$	61,617		100	%	$	229,009		100	%	$	528,481		100	%

A significant portion of our revenues are derived from a few major customers.  Customers with greater than 10% of total sales for the three and nine months ended September 30 are represented on the following table:

		Three Months Ended September 30,						Nine Months Ended September 30,
Customers	Product	2011			2010			2011			2010
Discus Dental, Inc.	Aphthasol®		25	%		38	%		22	%		37	%
Preston Wound Centers	Altrazeal®		12	%		---			*			---
ProStrakan, Ltd.	Zindaclin®		---			---			---			33	%
Total			37	%		38	%		22	%		70	%
* Sales from this customer were less than 10% of total sales for the period reported.